As a Biotech CEO, steering a company through the dynami […]
In the dynamic landscape of biotech, securing the right […]
Biotech research and development serve as the bedrock o […]
SHANGHAI AND PRINCETON, N.J. JUNE 09, 2023KYBORA Life S […]
In this report (download here) , Q1 2023 Global Biophar […]
KYBORA’s mission is to help life science companies achieve enduring success. Khai’s addition to our team allows us to provide additional value to our clients in China and Asia.
KYBORA is pleased to announce that its client Megalabs has acquired acquired Fr!ska.
KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.
KYBORA and its Chinese translation (pronounced KAI-BO-RUI) have both been granted official trademark status by the People’s Republic of China.
KYBORA is please to announce that its client Pint Pharma has completed an agreement to commercialize Orladeyo in Latin America
